WallStSmart

Adagene Inc (ADAG)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Adagene Inc generates 934% more annual revenue ($7.67M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -229.6%. RVMD earns a higher WallStSmart Score of 24/100 (F).

ADAG

Avoid

22

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: -5.22

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ADAGUndervalued (+89.5%)

Margin of Safety

+89.5%

Fair Value

$29.40

Current Price

$3.32

$26.08 discount

UndervaluedFair: $29.40Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADAG2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
7333.0%10/10

Revenue surging 7333.0% year-over-year

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ADAG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$249.75M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-144.5%2/10

ROE of -144.5% — below average capital efficiency

Free Cash FlowQuality
$-4.56M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ADAG

The strongest argument for ADAG centers on Revenue Growth, Debt/Equity. Revenue growth of 7333.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ADAG

The primary concerns for ADAG are EPS Growth, Market Cap, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ADAG profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ADAG is growing revenue faster at 7333.0% — sustainability is the question.

ADAG generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 22/100). ADAG offers better value entry with a 89.5% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adagene Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?